Glutathione S-transferase M1 and susceptibility to nasopharyngeal carcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 8, Issue 6, 1999, Pages 547-551

  Nazar Stewart, Valle ^a,b   Vaughan, Thomas L ^b,c   Burt, Richard D ^b   Chen, Chu ^b   Berwick, Marianne ^d   Swanson, G Marie ^e  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZO[A]PYRENE; GLUTATHIONE TRANSFERASE;

ADULT; AGED; ALCOHOL BLOOD LEVEL; ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; ENZYME ANALYSIS; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; TOBACCO;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ALCOHOL DRINKING; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; SEER PROGRAM; SEX DISTRIBUTION; SMOKING; UNITED STATES;

EID: 0033048354     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Hoffmann, D., and Hoffman, I. The changing cigarette. J. Toxicol. Environ. Health, 50: 307-364, 1997.
2. Nazar-Stewart, V., Motulsky, A. G., Eaton, D. L., White, E., Hornung, S. K., Leng, Z. T., Stapleton, P., and Weiss, N. S. The glutathione S-transferase μ polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res., 53: 2313-2318, 1992.
3. Seidegard, J., Pero, R. W., Markowitz, M. M., Rousch, G., Miller, D. G., and Beattie, E. J. Isoenzyme(s) of glutathione transferase (class μ.) as a marker for the susceptibility to lung cancer: a follow-up study. Carcinogenesis (Lond.), 11: 33-36, 1990.
4. London, S. J., Daly, A. K., Cooper, J., Navidi, W. C., Carpenter, C. I., and Idle, J. R. Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in LA County, CA. J. Natl. Cancer Inst. (Bethesda), 87: 1246-1253, 1995.
5. Kihara, M., Kihara, M., and Noda, K. Lung cancer risk of GSTM1 null genotype is dependent on the extent of smoking exposure. Carcinogenesis (Lond.), 15: 415-418, 1994.
6. Vaughan, T. L., Shapiro, J. A., Burt, R. D., Swanson, G. M., Berwick, M., Lynch, C. F., and Lyon, J. L. Nasopharyngeal cancer in a low-risk population: defining risk factors by histologic type. Cancer Epidemiol. Biomark. Prev., 5: 587-593, 1999.
7. Waksberg, J. Sampling methods for random digit dialing. J. Am. Stat. Assoc., 73: 40-46, 1978.
8. Miller, S. A., Dykes, D. D., and Polesky, H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res., 16: 1215, 1988.
9. Chen, C., Madeleine, M. M., Lubinski, C., Weiss, N. S., Tickman, E. W., and Daling, J. R. Glulathione S-transferase M1 genotypes and the risk of anal cancer: a population-based case-control study. Cancer Epidemiol. Biomark. Prev., 5: 985-991, 1996.
10. Breslow, N. E., and Day, N. E. Statistical Methods in Cancer Research. The Analysis of Case-Control Studies, Vol. 1. IARC Scientific Publ. No. 32, Lyon, France: IARC, 1991.
11. Kihara, M., Noda, K., and Kihara, M. Distribution of GSTM1 null genotype in relation to gender, age and smoking status in Japanese lung cancer patients. Pharmacogenetics, 5: S74-S79, 1995.
12. Zhong, S. Howie, A. F., Ketterer, B., Taylor, J., Hayes, J. D., Beckett, G. J., Wathen, C. G., Wolf, C. R., and Spurr, N. K. Glutathione S-transferase μ locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis (Lond.), 12: 1533-1537, 1991.
13. Alexandrie, A. K., Sunderg, M. I., Seidegard, J., Tonling, G., and Rannug, A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histologic cancer types. Carcinogenesis (Lond.), 15: 1785-1790, 1994.
14. Wilson, K. Sex-related differences in drug disposition in man. Clin. Pharmacokinet., 9: 189-202, 1984.
15. Gleiter, C. H., and Gundert-Remy, U. Gender differences in pharmacokinetics. Eur. J. Drug Metab. Pharmacokinet., 21: 123-128, 1996.
16. Harris, R. Z., Benet, L. Z., and Schwartz, J. B. Gender effectors in pharmacokinetics and pharmacodynamics. Drugs, 50: 222-239, 1995.
17. Troger, U., and Meyer, F. P. Influence of endogenous and exogenous effects on the pharmacokinetics of theophylline. Focus on biotransfonnation. Clin. Pharmacokinet., 28: 287-314, 1995.
18. Jones, B. M., and Jones, M. K. Alcohol effects in women during the menstrual cycle. Ann. N. Y. Acad. Sci ., 273: 576-587, 1976.
19. Fletcher, C. V., Acosta, E. P., and Strykowski, J. M. Gender differences in human pharmacokinetics and pharmacodynamics. J. Adolesc. Health, 15: 619-629, 1994.
20. Hildesheim, A., Anderson, L. M., Chen, C-J., Cheng, Y-J., Brinton, L. A., Daly, A. K., Reed, C. D., Chen, I-H., Caparaso, N. E., Hsu, M-M., Chen, J-Y., Idle, J. R., Hoover, R. N., Yang, C-S., and Chhabra, S. K. CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J. Natl. Cancer Inst (Bethesda), 89: 1207-1212, 1997.
21. Uematsu, F., Kikuchi, H., Abe, T., Motomiya, M., Ohmachi, T., Sagami, I., and Watanabe, M. Msp1 polymorphism of the human CYP2E gene. Nucleic Acids Res., 19: 5797, 1991.
22. Uematsu, F., Kikuchi, H., Motomiya, M., Abe, T., Ishioka, C., Kanamaru, R., Sagami, I., and Watanabe, M. Human cytochrome P450IIE1 gene: DraI polymorphism and susceptibility to cancer. Tohoku J. Exp. Med., 168: 113-117, 1992.
23. Persson, I., Johansson, I., Bergling, H., Dahl, M-L, Seidegård, J., Rylander, R., Rannug, A., Högberg, J., and Ingleman-Sundberg, M. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett., 319: 207-211, 1993.
24. Kelsey, K. T., Hankinson, S. E., Colditz, G. A., Springer, K., Garcia-Closas, M., Spiegelman, D., Manson, J. E., Garland, M., Stampfer, M. J., Willett, W. C., Speizer, F. E., and Hunter, D. J. Glutathione S-transferase class μ deletion polymorphism and breast cancer: results from prevalent versus incident cases. Cancer Epidemiol. Biomark. Prev., 6: 511-515, 1997.
25. Anwar, W. A., Abdul-Rahman, S. Z., El-Zein, R. A., Mostafa, H. M., and Au, W. W. Genetic Polymorphisms of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis (Lond.), 17: 1923-1929, 1996.
26. Brockmoller, J., Cascorbi, I., Kerb, R., and Roots, I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferase M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res., 56: 3915-3925, 1995.
27. Trizna, Z., Clayman, G. L., Spitz, M. R., Briggs, K. L., and Goepfert, H. Glutathione S-transferase genotypes as risk factors for head and neck cancer. Am. J. Surg., 17: 499-501, 1995.